Monograph
J07AN01 - Tuberculosis, Live Attenuated |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the tuberculosis, live attenuated vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Live attenuated Mycobacterium bovis BCG (Bacillus Calmette-Guérin).
Therapeutic characteristics
The tuberculosis, live attenuated vaccine (BCG vaccine) is indicated for active immunization against against tuberculosis in individuals from the age of 6 weeks to 35 years.
It is administered as a single intradermal injection.
Metabolism and pharmacokinetics
The BCG vaccine is not metabolized by the cytochrome P450 system.
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
|
|
| * | Summary of Product Characteristics | |
| 2. | Norwegian medicines agency. Summary of Product Characteristics (SPC). BCG-vaksine SSI.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Denmark
Norway
Poland
Finland
Latvia
Serbia© NAPOS 2024